This was very close to the study data reported by White et al.,11 in which the patients with advanced EGFR‐mutant lung cancer received platinum doublet chemotherapy regimens after progression on osimertinib got a median time on treatment of 3.9 months (95% CI 1.9–7.8 months) and OS of 12.8 months (95% CI 6.9–19.5 months), indicating a comparable efficacy of later‐line dacomitinib and chemotherapy. The gene discussed is EGFR; the disease is lung carcinoma.